Biosimilar sponsors are worried that interchangeability, or lack thereof, could be used against them by reference product manufacturers to limit uptake and question product quality.
Because interchangeability is considered a higher bar for FDA approval than biosimilarity, sales representatives, presumably for innovator products, have suggested to providers that they should wait for the biosimilar to receive interchangeability status before using it, said Hillel Cohen,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?